FIELD: medicine.
SUBSTANCE: invention relates to the field of biotechnology and medicine, in particular, to an antifibrin antibody and to a polypeptide containing said antifibrin antibody and a fragment of serine protease of the human tissue plasminogen activator (hu-tPA). Also proposed is a method for treating thrombosis in a subject in need thereof using the above polypeptide.
EFFECT: treatment of thrombosis by means of an antifibrin antibody.
17 cl, 22 dwg, 1 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITE POLYPEPTIDE HAVING METAL-BINDING MOTIF AND MOLECULAR STRUCTURE CONTAINING THEREOF | 2020 |
|
RU2814475C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
